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Abstract  36 
 37 
Blood citrulline and intestinal fatty acid binding protein were determined as biomarkers for 38 
intestinal mucositis. Biomarker levels were correlated with corresponding serum 1,3-beta-d-39 
glucan levels in 56 samples obtained from 33 cases with underlying hematological 40 
malignancies receiving induction chemotherapy. No correlation between biomarkers of 41 
intestinal mucositis and BDG levels was observed. 42 
  43 
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 (1→3)-β-D-Glucan (BDG) is a polysaccharide cell wall component of most fungal species 44 
and a useful serum biomarker for early diagnosis of invasive fungal infections (IFIs) (1, 2). 45 
False positive results have been linked to use of cellulose containing haemodialysis 46 
membranes, blood-derivates, broad spectrum antibiotics, and severe mucositis (3). Intestinal 47 
mucositis is a frequently observed adverse event of induction chemotherapy in patients with 48 
underlying hematological malignancies (4). Severe mucositis is characterized by a loss of 49 
integrity of the intestinal mucosal barrier, increasing the likelihood of translocation of 50 
bacterial and/or fungal commensals of the gastrointestinal tract (5). Whether intestinal 51 
mucositis is a cause of false positive BDG serum levels has been insufficiently evaluated to 52 
date mainly because of difficulties in diagnosing and defining mucositis in hematological 53 
malignancy patients in clinical routine. Biopsy of the gastrointestinal tract is the diagnostic 54 
gold-standard, but often hindered by the unfavorable risk-benefit ratio in those with severe 55 
underlying conditions and increased risk of bleeding.  56 
Thus, several clinical scores have been implemented for diagnosis and grading of mucositis 57 
(6, 7), but these are prone to subjective interpretation. Therefore, noninvasive diagnostic 58 
biomarkers for mucositis have been increasingly investigated. Serum citrulline, a non-protein 59 
amino acid produced by intact enterocytes (8, 9), and intestinal fatty acid binding protein 60 
(IFABP), low-molecular mass cytosolic proteins found in tissues involved in the uptake, 61 
intracellular metabolism and transport of long-chain fatty acids (10, 11), are two of the most 62 
promising biomarkers for detection of loss of enterocytes and therefore mucosal barrier 63 
injury.  64 
The objective of this study was to investigate whether serum BDG levels are falsely elevated 65 
in hematological malignancy patients with intestinal mucositis. A total of 56 same day plasma 66 
and serum samples, were prospectively obtained from 33 consecutive cases (i.e. 33 67 
admissions corresponding to 24 patients; maximum 2 samples per case) with underlying 68 
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hematological malignancies receiving induction chemotherapy for acute leukemia. None of 69 
our patients fulfilled criteria for IFI according to 2008 revised definitions for IFIs from the 70 
EORTC/MSG group (12, 13). Samples were collected between July 2012 and May 2013 at 71 
the University Hospital of Graz, Austria, and a maximum of two samples per case were 72 
included (in those with two samples, samples were obtained always > 4 days apart). BDG was 73 
determined prospectively, while citrulline and IFABP were determined retrospectively in 74 
serum/plasma samples after immediate sample storage at -70° at the Medical University of 75 
Graz, Austria. BDG was determined using the automated protocol Fungitell® assay 76 
(Associates of Cape Cod, Inc., East Falmouth, USA), as described previously (14). IFABP 77 
was determined using the Quantikine Human FABP2/I-FABP Immunoassay (R&D Systems 78 
Europe Ltd., OX, UK) according to the manufacturer’s instruction. Citrulline was determined 79 
from plasma samples at the University Hospital Leuven, Belgium, using liquid 80 
chromatograph-tandem mass spectrometry as described elsewhere (15). Mucositis was 81 
classified according to citrulline levels: >30µmol/L as no evidence of mucositis, 20-30µmol/L 82 
as partial villus atrophy, 10-20µmol/L as destructive mucosal lesions and <10µmol/L as 83 
diffuse destructive mucositis (16, 17). IFABP was used as a second marker for mucositis to 84 
better support mucositis classification based on citrulline levels. In contrast to citrulline 85 
IFABP levels are highly elevated in case of intestinal mucosal barrier damage, with 100 fold 86 
increases in patients with intestinal ischemia when compared to healthy controls (10).  87 
For statistical analyses a cut-off of 10µmol/L citrulline was used as indicator for extensive 88 
mucositis. The study adhered to the Declaration of Helsinki (1996) and Good Clinical 89 
Practice. The study protocol was approved by the local ethics committee, Medical University 90 
Graz, Austria (EC-number 23-343) and registered at ClinicalTrials.gov (identifier 91 
NCT01576653). Informed consent was obtained from all participating patients. For statistical 92 
analysis SPSS Version 23 was used (SPSS Inc., Chicago, IL, USA). For continuous variables 93 
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medians plus interquartile range (IQR) or mean plus 95% confidence interval (95% CI) are 94 
displayed as appropriate. Correlation analysis was performed by using Spearman-Rho 95 
analyses due to non-normality of our data and data are presented in scatterplots. Retrospective 96 
power analysis revealed that a sample size of 48 mucositis samples (8 samples were derived 97 
from patients without mucositis) provides at least 80% power (with alpha = 0.05) to detect a 98 
correlation of r=0.44 (i.e. r2=0.19) or higher for correlations of three variables. Chi-squared 99 
test was used for categorical data. A p-value of <0.05 was considered statistically significant. 100 
Demographic data, underlying diseases, and biomarker levels for patients, cases and samples 101 
are displayed in Table1. All patients were receiving mold-active antifungal prophylaxis with 102 
posaconazole oral suspension, as recommended in clinical guidelines. Additionally, all 103 
included patients were able to tolerate solid food. All but two patients were on systemic 104 
antibiotic treatment/prophylaxis at the time of sample collection. Most common antibiotics 105 
prescribed at the time of sampling were: levofloxacin (23 samples, 42.6%), cefepime (21 106 
samples, 38.9%), linezolid (7 samples, 13%) and meropenem (6 samples, 11.1%). 107 
Additionally, all patient received prophylaxis for oral mucositis containing chlorhexidine 108 
mouth wash and nystatin oral solution. Overall specificity of serum BDG testing in our cohort 109 
was 0.95 (95% CI 0.85 – 0.98). 110 
Positive BDG serum levels (>80pg/ml) were observed in three serum samples: two out of 17 111 
samples (11.8%) with citrulline levels <10µmol/L had false positive BDG levels (120.5pg/ml 112 
and 149.3pg/ml respectively; corresponding IFABP levels: 1366.3pg/ml and 976.1pg/ml 113 
respectivley) and one out of 39 samples (2.6%) with citrulline levels ≥10µmol/L had a false 114 
positive BDG level (232.4pg/ml; corresponding IFABP level: 380.1pg/ml; p=0.160). Median 115 
BDG levels in samples with citrulline levels <10µmol/L and ≥10µmol/L were 15.4pg/ml in 116 
both groups. Serum IFABP levels showed a strong negative correlation with plasma citrulline 117 
levels (Spearman-Rho r=-0.601; p=<0.001). Additionally, IFABP values were significantly 118 
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higher in the mucositis group (i.e. n=17 with <10µmol/L citrulline) compared to the group 119 
without severe mucositis according to citrulline levels (814.8pg/ml versus 380.9pg/ml; 120 
p=0.004) supporting mucositis diagnosis based on citrulline levels. Correlations between 121 
BDG and citrulline, or IFABP are displayed in Figure 1. 122 
Our main objective in this study was to determine whether underlying intestinal mucositis in 123 
hematological malignancy patients is a potential cause of falsely elevated serum BDG levels.  124 
As surrogate markers for mucositis we used citrulline and IFABP. Both markers showed 125 
excellent correlation with each other supporting the diagnosis of intestinal mucositis, 126 
however, no correlation between either citrulline or IFABP and serum BDG levels was 127 
observed. Additionally, only 2 out of 17 samples from patients with biomarker levels 128 
suggestive for diffuse intestinal mucosal lesion yielded positive serum BDG levels.  129 
As fungi, especially Candida spp., are commensals in the gastrointestinal tract, mucosal 130 
barrier damage is considered a risk factor for developing IFIs (18, 19). Antifungal prophylaxis 131 
is therefore a recommended practice in patients with hematological malignancies receiving 132 
induction chemotherapy or hematopoietic stem cell transplantation (20). In our setting oral 133 
posaconazole suspension was used as prophylactic agent in all patients. Antifungal 134 
prophylaxis is likely to result in a decreased fungal burden in the gastrointestinal tract and 135 
therefore a reduced amount of fungal components in serum in case of mucosal barrier 136 
damage. This may be particularly true for the posaconazole suspension that was used in all 137 
our patients. Due to the liquid formulation, posaconazole suspension is acting more fungicidal 138 
in the upper gastrointestinal tract (i.e. oral, esophagus) when compared to the newer tablet 139 
formulation. As fungal colonization is mainly found in the upper gastrointestinal tract, 140 
posaconazole suspension may cause more substantial reduction of fungal colonization when 141 
compared to the tablet or the intravenous form. While the fact that antifungal prophylaxis was 142 
used in all participants may be considered a limitation from a scientific standpoint (i.e. we 143 
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could not evaluate whether mucositis is associated with false positive BDG levels in the 144 
absence of antifungal prophylaxis), it may be considered as strength from a clinical standpoint 145 
as this reflects clinical practice in most specialized centers.  146 
Specificity of serum BDG testing in our study was 95% which is comparable to other studies 147 
in hematological malignancy patients (21). Our results therefore clearly indicate that 148 
mucositis may not be a major cause of false positive BDG levels in patients with induction 149 
chemotherapy, receiving antifungal prophylaxis. These findings have important clinical 150 
implications, as false negative BDG test results in the presence of antifungal therapy or 151 
prophylaxis have been shown to occur rarely. This is supported by a study conducted by Koo 152 
et al., who could demonstrate that systemic antifungal therapy did not alter the performance of 153 
serum BDG determination (22).  154 
Our study was limited by indirect assessment of intestinal mucositis by citrulline and IFABP 155 
determination. No endoscopies to verify intestinal mucosal barrier damage were performed. 156 
Additionally, citrulline and IFABP are both produced in the lower gastrointestinal tract, and 157 
may not be very reliable biomarkers in patients with exclusively oral mucositis. Oral 158 
mucositis may have therefore been underestimated in our study. Small samples size was 159 
another important limitation.  160 
In conclusion, we did not observe elevated serum BDG levels in hematological malignancy 161 
patients with underlying intestinal mucositis who received antifungal prophylaxis, indicating 162 
that serum BDG may be a specific biomarker in this setting. 163 
 164 
 165 
 166 
 167 
 168 
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Figure 1 Correlation of 1,3-beta-d-glucan (BDG) with citrulline and intestinal fatty acid 302 
binding protein (IFABP) in same day plasma and serum samples. Correlation analyses 303 
were performed by Spearman-Rho-analysis and yielded no significant correlations between 304 
BDG and citrulline (r=0.081) and BDG and IFABP (r=0.048).  305 
 306 
Table 1 Demographic data, underlying diseases and 1,3-beta-d-glucan (BDG), citrulline and intestinal fatty acid binding protein (IFABP) levels in  
the study population. 
 Patients* [n (%)] Cases** [n (%)] Samples*** [n (%)] 
N 
 
24 33 56 
Sex: Female / Male 10 (41.7) / 14 (58.3) 15 (45.5) / 18 (54.5) 28 (50) / 28 (50)
Age, years (range) 
 
54 (20-67) 57 (20-67) 59 (20-67) 
Underlying diseases    
Acute myeloid leukemia 18 (75) 26 (78.8) 46 (82.1)
Acute lymphoblastic leukemia 3 (12.5) 4 (12.1) 5 (8.9) 
Myelodysplastic syndrome 2 (8.3) 2 (6.1) 3 (5.4) 
Aplastic anemia 
 
1 (4.2) 1 (3) 2 (3.6) 
Citrulline µmol/L, median (IQR)  14.3 (8.6-33.6) 14.1 (8.8-18.2) 13.8 (8.7-18.2) 
Citrulline <10µmol/L   
(diffuse destructive mucositis) 
8 (33.3) 11 (33.3) 17 (30.4) 
Citrulline 10-20µmol/L  
(destructive mucosal lesions) 
12 (50) 18 (54.5) 31 (55.4) 
Citrulline 20-30µmol/L 
(partial villus atrophy) 
1 (4.2) 1 (3) 4 (7.1) 
Citrulline ≥30µmol/L 
(no evidence of mucositis) 
3 (12.5) 3 (9.1) 4 (7.1)
BDG pg/ml, median (IQR) 15.4 (7.4-39.9) 15.4 (5-35.8) 15.4  (6.8-30.9)
BDG ≥80pg/ml 2 (8.3) 2 (6.1) 3 (5.4) 
BDG <80pg/ml 
 
22 (91.7) 31 (93.9) 53 (94.6) 
IFABP pg/ml, median (IQR) 524.6 (309.8-804.3) 483.5 (332.3-849.7) 514.9 (337.9-792.6)
Severe Diarrhea 3 (12.5) 3 (9.1) 4 (7.1)
Citrulline <10µmol/L (diffuse 1 (33.3) 1 (33.3) 2 (50) 
destructive mucositis) 
Citrulline 10-20µmol/L (destructive 
mucosal lesions) 
2 (66.6) 2 (66.6) 2 (50) 
Absolute numbers plus percentage displayed, unless otherwise noted. 
*Patients = first sample per patient within the study period; **Cases = 33 admissions corresponding to 24 patients; ***Samples = all samples obtained from included patients within the study 
period 
Abbreviations: BDG = 1,3-beta-d-glucan; IQR = 25 -75 interquartile range; IFABP = intestinal fatty acid binding protein
 

